# A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

> **NCT05321082** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1178 (actual)

## Conditions studied

- Lung Diseases, Interstitial

## Interventions

- **DRUG:** BI 1015550
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05321082
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-16
- **Primary completion:** 2024-12-18
- **Final completion:** 2025-04-14
- **Target enrollment:** 1178 (ACTUAL)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05321082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05321082, "A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05321082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*